What question did this study set out to answer?

To define the interactions between prostaglandin D2 and its receptors on human platelets.

August 1, 1979Journal of Clinical InvestigationOpen Access

Characterization of the Platelet Prostaglandin D2 Receptor

Q: What is the clinical evidence from this study?

Study design: Case-Control. Population: Myeloproliferative disorders (n=16). Intervention: Myeloproliferative disorders vs. Normal volunteers. Primary outcome: [3H]PGD2 binding to platelets (fmol ligand bound/10^8 platelets) (53% decrease, p=<0.01).

View Full Paper

Ask AI

Bookmark

Key result

Platelets from patients with myeloproliferative disorders exhibited a 53% decrease in [3H]PGD2 binding compared to normal platelets (7.1 vs 15.1 fmol/10^8 platelets, P<0.01), indicating a loss of PGD2 receptors.

Key Points

To define the interactions between prostaglandin D2 and its receptors on human platelets.
Developed a binding assay for platelet PG receptors using [(3)H]PGD(2) as ligand.
Conducted Scatchard analysis of binding data from normal subjects and patients with certain blood disorders.
Measured PGD(2) binding in normal and patient platelets to assess differences.
Patients' platelets showed a 53% decrease in [(3)H]PGD(2) binding compared to normal platelets (P < 0.01).
The K(d) for [(3)H]PGD(2) binding was comparable in normal (53 nM) and patient platelets (33 nM).
A 48% decrease in PGD(2)-activated platelet adenylate cyclase activity corresponded with the decrease in binding.

Study Design

Type

Case-Control (n=16)

Multicenter

Yes

Structured PICO

Population

16 subjects, including 5 patients with myeloproliferative disorders, 6 normal volunteers, and 5 patients with reactive thrombocytosis, were studied to characterize platelet PGD2 receptors.

Exposure

In vitro [3H]PGD2 radioligand binding assay and adenylate cyclase activation assay

Comparator

Platelets from normal volunteers

Outcome

Number of PGD2 binding sites per platelet and dissociation constant (Kd)surrogate

Main Result

Effect estimate: 53% decrease

Absolute Event Rate: 7.1% vs 15.1%

p-value: p=<0.01

The study characterizes a specific platelet PGD2 receptor and demonstrates its selective loss in patients with myeloproliferative disorders, explaining their resistance to PGD2-mediated inhibition of aggregation.

Limitations

Small sample size

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

PGD2 receptor loss may underlie platelet resistance in myeloproliferative disorders; leaves open whether receptor modulation alters outcomes.

Cite This Study

Cooper et al. (1979) conducted a case-control in Myeloproliferative disorders (n=16). Myeloproliferative disorders vs. Normal volunteers was evaluated on [3H]PGD2 binding to platelets (fmol ligand bound/10^8 platelets) (53% decrease, p=<0.01). Platelets from patients with myeloproliferative disorders exhibited a 53% decrease in [3H]PGD2 binding compared to normal platelets (7.1 vs 15.1 fmol/10^8 platelets, P<0.01), indicating a loss of PGD2 receptors.

synapsesocial.com/papers/6a32fb3c9fde5acd9fb14879 https://doi.org/10.1172/jci109497

View Full Paper

Ask AI

Bookmark

Implication

PGD2 receptor loss may underlie platelet resistance in myeloproliferative disorders; leaves open whether receptor modulation alters outcomes.

Characterization of the Platelet Prostaglandin D2 Receptor

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Characterization of the Platelet Prostaglandin D2 Receptor

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider